Thyroid disease in general, and hypothyroidism in particular, are very common in women. In the USA, the most common cause of primary thyroid deficiency is on an autoimmune basis due to lymphocytic (Hashimoto) thyroiditis. Because there are thyroid hormone receptors in virtually every tissue of the body, the manifestations of hypothyroidism are varied, but problems with abnormal menses, conception, fertility, and pregnancy can be especially troubling in young women. The single most important diagnostic test is measurement of serum thyrotropin (TSH). The overwhelming majority of patients with hypothyroidism are treated with a single daily dose of synthetic levothyroxine with the goal of therapy being restoration of a normal metabolic state with return of the TSH level down to the range of 0.5 to 1.5 mlU/L. "Subclinical" hypothyroidism refers to those patients with early or mild thyroid hypofunction manifested as slight elevations of thyrotropin (ϳ4-10 mlU/L) although serum thyroxine (T4) and triiodothyronine (T3) levels are within their reference ranges. The entity is somewhat controversial in regard to its consequences if left untreated, and whether or not we should be screening patients, at least susceptible populations, for the condition. Reports indicate an association between subclinical hypothyroidism and poor outcomes of pregnancy, as well as dyslipidemias, atherogenesis, and increased mortality in the long term. We believe these consequences are sufficiently compelling to warrant screening and treatment with levothyroxine when found to halt progression to overt hypothyroidism, and improve symptoms, pregnancy outcomes, lipid abnormalities, and cardiovascular function.
Thyroid hormone deficiency from any cause results in hypothyroidism. The lack of thyroid hormone may be primary, ie, resulting from a defect in the thyroid gland itself, or secondary, ie, resulting from thyrotropin (TSH) deficiency related to pituitary or hypothalamic disease. This discussion focuses only on primary hypothyroidism. In adult women, virtually 95% of all cases of hypothyroidism are the result of primary disease of the thyroid gland, the most common of which is on an autoimmune basis and is the result of lymphocytic (Hashimoto) thyroiditis. It is likely that antithyroperoxidase antibodies present in this condition are cytotoxic and directed against thyroid follicular cells leading ultimately to death of the cells, thyroid atrophy, and hypothyroidism.
Hashimoto disease is some 5 to 8 times more common in women than men and may coexist with diabetes mellitus and other diseases in which circulating autoantibodies are found such as Sjögren syndrome, pernicious anemia, systemic lupus erythematosus, rheumatoid arthritis, primary biliary cirrhosis, and chronic hepatitis. Rarely, hypothyroidism may also be a manifestation of a polyglandular endocrine deficiency state in which various autoantibodies cause impaired function of the adrenal, parathyroid, and gonads in addition to the thyroid. Some patients with Hashimoto disease may present with goiter rather than an atrophic gland, and in many cases, the goiter is actually the result of lymphocytic infiltrates within the thyroid. Patients will be euthyroid until there is sufficient loss of functioning thyroid follicular cells to cause hypothyroidism. In the earliest stages of evolution, the hypothyroidism may be "subclinical" (see subsequently). However, even when still euthyroid, patients with Hashimoto disease may be uniquely sensitive to exposure to exogenous iodine excess and develop iodine-induced hypothyroidism.
CLINICAL PRESENTATION
Signs and symptoms of hypothyroidism will vary greatly depending on the severity and duration of the thyroid deficiency, the age of the patient, and the possible coincidence of other systemic illness. Early symptoms of hypothyroidism are often nonspecific and insidious in onset and may include fatigue, lethargy, constipation, cold intolerance, muscle stiffness and cramping, carpal tunnel syndrome, decreased libido, depression, hair loss, menstrual irregularity, menorrhagia, and infertility. In the older woman, the symptoms may be erroneously attributed to the aging process or to other common disorders of the elderly such as Parkinson disease, depression, or Alzheimer disease. Along with apathy, there is slowing in mental agility and motor activity, reduced memory, and some weight gain despite a reduced appetite. The skin and hair become dry, and the hair becomes thinner as it falls out. Hearing becomes impaired, and edema of the vocal cords may account for deepening of the voice. Somnolence is common, and enlargement of the tongue contributes to a tendency to obstructive sleep apnea.
With little functional thyroid reserve, the severity of hypothyroidism can progress to a clinical picture of florid myxedema. At this stage, patients appear pallid, depressed, and hypokinetic with a hoarse voice, dull, expressionless facies, sparse hair, and a large tongue. The skin is cool to touch, dry, rough, or scaly, and there is facial and periorbital puffiness and often generalized edema. Fluid may collect in various body compartments, and pleural effusion, pericardial effusion, or ascites are not uncommon. Goiter may or may not be present depending on the etiology of the hypothyroidism and, as mentioned previously, the gland is atrophic and usually not palpable in primary myxedema as a result of burned out Hashimoto disease.
On physical examination or chest x-ray, the cardiac silhouette will appear enlarged that may be the result of either chamber dilatation or pericardial effusion. A small cardiac silhouette should bring adrenal insufficiency to mind either on a pituitary basis or as a result of coincident primary adrenal insufficiency (Schmidt syndrome). Constipation is common as a result of slowed gastrointestinal motility, and adynamic ileus may cause megacolon or intestinal obstruction. A psychiatric syndrome ("myxedema madness") has been described, and neurologic findings include a delayed or hung-up relaxation phase of deep tendon reflexes, muscle weakness, and ataxia.
LABORATORY DIAGNOSIS
The single most important diagnostic test is measurement of the serum TSH, which is increased in patients with primary thyroid disease. Serum total and free thyroxine (T4) will be decreased in all forms of hypothyroidism. Measurement of serum total triiodothyronine (T3) is less useful and may be within the normal range in the majority of patients with hypothyroidism. Thyroid autoantibodies (anti-TPO and antithyroglobulin less frequently) will be detectable in the majority of patients. The radioiodine uptake may be normal to actually elevated in Hashimoto disease but is usually decreased in overt hypothyroidism. The uptake can be elevated because the sodium iodide symporter may be intact until late in the disease, whereas thyroid hormone synthesis is disturbed earlier leading to low levels of serum thyroxine and high levels of TSH. The high TSH serves to further stimulate the transport of iodine leading to a high uptake.
Other nonthyroid laboratory tests may provide further clues to the presence of hypothyroidism. Serum triglycerides and total and low-density lipoprotein cholesterol level are usually elevated in hypothyroidism as well as levels of carotene, creatine phosphokinase (CPK), aspartate transaminase, and lactate dehydrogenase. Anemia may be present on the basis of impaired iron utilization, and in patients with Hashimoto disease, there may be coincident pernicious anemia in approximately 10% of patients. Electrocardiographic changes include bradycardia, low-amplitude QRS complexes, and flattened or inverted T waves, findings that may be most pronounced in the presence of a pericardial effusion. Cardiac contractility is reduced as can be assessed by systolic time intervals demonstrating a prolonged preejection period and an increased ratio of the preejection period to the left ventricular ejection time.
TREATMENT OF OVERT HYPOTHYROIDISM
Levothyroxine is the overwhelming choice of clinicians for the treatment of hypothyroidism, and monitoring of serum TSH levels is required for appropriate dosage adjustment. The medication has a narrow therapeutic index, and either underdosage ("subclinical" hypothyroidism) or excessive dosage ("subclinical" hyperthyroidism) will be associated with adverse symptoms and pathophysiological effects and is to be avoided. The consequent necessity for careful titration of dosage has had impact on the issue of "switchability" or bioequivalence of the various levothyroxine products marketed. The position of the American Thyroid Association, American Association of Clinical Endocrinologists, and The Endocrine Society is that only branded preparations (not generics) should be used; that patients should stay on the same brand; and TSH should be remeasured in 6 weeks and dosage retitrated if a switch to a different brand is required.
Patients should require only a single daily dose of synthetic levothyroxine because of its long (6-7 days) half-life. Other thyroid hormone preparations are available and include desiccated thyroid extract USP, a triiodothyronine (T3) preparation, and a mixture of thyroxine and T3 (liotrix). Although once in popular use, the thyroid extract preparation is no longer recommended for a number of reasons, principal of which is because of its content of T3 that is so rapidly absorbed that the resultant high serum T3 can cause worrisome tachycardias or other arrhythmias in elderly patients or those with underlying cardiac disease. Levothyroxine is more stable and has a longer, more predictable shelf life. Because T4 is converted to T3 physiologically, ultimately, near-normal concentrations of serum T3 can be restored by administering thyroxine alone. To more closely mimic thyroidal T3 secretion and normal blood levels, oral supplements of triiodothyronine would need to be given in frequent divided dosage, a regimen that makes good compliance problematic. Moreover, convincing arguments or data demonstrating benefit of concomitant T3 administration are lacking. When initially diagnosed, most cases of hypothyroidism have existed for some time, and there is usually (with the exception of myxedema coma) no reason to rapidly correct the thyroid deficiency with aggressive therapy. In young women, one could start with 75 to 88 g/day. In older patients and especially in those with underlying heart disease, dosage is gradually incremented with an initial daily dose of 25 to 50 g thyroxine increased by 25 g at 4-to 6-week intervals until a normal metabolic state is attained. The best indication that a normal metabolic state has been attained is normalization of the TSH level down to the range of 0.5 to 1.5 mU/L. On average, this will equate to an ultimate full replacement dose of approximately 1.7 g/kg per day. Patients who have had a total thyroidectomy, eg, for thyroid malignancy, especially when surgery was followed by radioiodine ablation, will have no residual thyroid tissue and their requirement will be closer to 2.1 g/kg per day. Although it has been shown in one small series of patients that full replacement dosage of T4 may be safely initiated (1), we have argued that this is potentially dangerous (2), especially in the elderly and in patients with heart disease, because a sudden increase in metabolic rate may tax cardiac or coronary reserve.
In some circumstances, a previously stable dosage of levothyroxine may need to be increased or decreased. Increases of 25 to 50 g per day are generally required during pregnancy, as evidenced by increases in serum TSH, and some workers have advocated routinely increasing the dose once pregnancy has been determined (3) . Progressive increases in dose may be required because further atrophy of the gland occurs in patients with Hashimoto disease or in patients with Graves disease who have been treated with surgery or radioiodine. On the other hand, a need to reduce thyroxine dosage may be indicated by the spontaneous disappearance of TSH receptor blocking antibodies in Hashimoto disease or increases in stimulating TSH receptor antibodies leading to evolution of autonomy in a previously treated Graves gland or emergence of autonomous hyperfunction in a uninodular or multinodular goiter.
Gastrointestinal absorption of T4 may be slightly reduced when taken with food or certain other pharmacologic agents that interfere with gastrointestinal absorption or enhance the metabolic clearance of T4. Thus, coingestion of Carafate, cholestyramine, colestipol, ferrous sulfate, or calcium carbonate will result in reduced absorption of T4. Simultaneous therapy with either phenytoin (dilantin) or carbamazepine (Tegretol) will lead to enhanced metabolism and disposition of T4, and the dosage will need to be increased in the absence of any endogenous thyroid Thyroid Disease in Women Y CME Review Article 537
reserve. Finally, it is very important to remember that modest elevations in the TSH can be transient, and no harm will arise from postponing initiation of therapy until the high TSH might be confirmed by a repeat measurement in 8 to 12 weeks (4).
SUBCLINICAL (MILD) HYPOTHYROIDISM
Like with many disorders, patients with hypothyroidism may present earlier or later in the course of their disease. In its earliest, mild form, hypothyroidism has been called "subclinical" because the symptoms may be so mild as to be overlooked. Other designations for this condition have include "minimally symptomatic hypothyroidism" or "mild thyroid failure" or "early thyroid failure" (5-7). The significant point is that thyroid failure is present although the routine thyroid function tests such as total and free T4 or T3 will still be within the "normal" or reference range, albeit probably lower than when the patients were truly euthyroid. Consequently, the diagnosis of subclinical disease rests on the finding of a slight elevation in serum TSH. These patients with an isolated slight elevation in serum TSH have been presumed to be asymptomatic and hence the "subclinical" designation. Designating this clinical entity as early or mild hypothyroidism makes somewhat more physiological sense.
Patients with mild thyroid failure have been traditionally thought to be asymptomatic, but they may present to the gynecologist with menstrual irregularities or infertility. A more detailed history and physical may reveal several symptoms and signs seen in overt hypothyroidism and potentially attributable to thyroid hypofunction such as fatigue, depression, loss of energy, muscle weakness, dry skin, and sleep disturbances. Several laboratory abnormalities, as described subsequently, could also be attributed to this condition. In addition to Hashimoto thyroiditis as a cause of early thyroid failure, other etiologies include thyroid ablation with radioactive iodine, antithyroid drugs (eg, PTU), external beam radiation, partial thyroidectomy, or drugs such as amiodarone, lithium, or radiographic contrast agents.
A serum measurement of TSH provides us with an insight into the adequacy of circulating levels of T4 or T3 in the peripheral tissues. Thus, even the slightest elevation in TSH implies a lack of thyroid hormone at the tissue level, the tissue in the case of TSH measurements being the pituitary gland, which we infer to be representative of other tissues as well. Although reference ranges for TSH are often as broad as 0.3 to 6.5 mU/L, it is our contention that a truly normal serum TSH ranges between 0.3 and 2.5 with levels between 2.5 and 4.0 being in a "gray zone" deserving of subsequent follow up and values of Ͼ4.0 as indicative or early or mild thyroid failure (even if serum T4 and T3 are still within the "normal" range) (8) . Usually, it is not possible to know a given woman's optimal TSH "set point" because we are not likely to have any premorbid original TSH measurement until she presents with suspected thyroid disease.
Laboratory reference ranges are usually based on the range of values found in a large sample of ostensibly normal subjects. Such populations are contaminated by subjects with occult underlying thyroid disease who may have antithyroid antibodies or a family history of autoimmune thyroid disease. When such subjects are excluded from the "normal" blood donor pool, the normal reference range becomes 0.4 to 2.5 mIU/L (9). This narrow true normal range is consistent with findings of the NHANES III study as well as consensus guideline C.11 of the National Academy of Clinical Biochemistry (NACB) (10) . As indicated previously, it remains controversial whether early or mild thyroid failure is associated with significant adverse clinical consequences (11) . Those who believe it may have a clinical impact will recommend initiation of thyroxine therapy (12) (13) (14) (15) , whereas those who do not will tend to recommend observation and follow-up TSH testing (16, 17) . Recently, an expert panel convened by the Endocrine Society, American Thyroid Association, and American Association of Clinical Endocrinologists examined the evidence for clinical impact (18) . Their conclusions were controversial in that reviewers representing all 3 sponsoring professional organizations disagreed with the conclusions of the panel (19) . Both sides of the controversy have since been further examined (20, 21) . As indicated previously, an underlying critical issue is the definition of a "normal" reference range for TSH. NACB guidelines (10) state that "greater than 95% of healthy, euthyroid subjects have a serum TSH concentration between 0.4 and 2.5 mU/liter." They go on further to state that "Ambulatory patients with a serum TSH Ͼ2.5 mU/liter, when confirmed by repeat TSH measurement made after
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Obstetrical and Gynecological Survey 3-4 weeks, may be in the early stages of thyroid failure, especially if TPO-Ab is detected." Thus, it seems logical to us that those patients who are TPOAb-positive should be excluded from populations used to derive a normal TSH reference range. In doing so, one recognizes that this TPO-Ab-positive population has Hashimoto disease, is vulnerable to progression to overt hypothyroidism, and may be "contaminating" the otherwise normal population sampled. Recently revised thyroid disease guidelines of the American Association of Clinical Endocrinologists proposed a reference TSH range of 0.3 to 3.0 mU/L (22) . Depending on the cutoff value for TSH used to define "mild thyroid failure," its prevalence will vary. With the traditionally used, but in our view too high, upper level limit cutoff value of 4.5 mU/L, a prevalence of 1.1% and 4.5% has been found in black and white women, respectively (9) . Prevalence seems to increase with age, becoming as high as 12.9% by the eighth decade of life. Factors that are thought to be associated with increased likelihood of mild hypothyroidism include white race, high iodine intake (urinary iodide Ͼ1 mgm/Gm creatinine), and positive antithyroid antibodies. The greater incidence in whites than in blacks is consistent with the mean normal values found in the NHANES population of 1.18 mU/L in blacks and 1.40 mU/L in whites (9) . Mild thyroid failure is found more frequently in women with other autoimmune diseases such as diabetes mellitus. It is thought, for example, that up to 25% of pregnant women with diabetes will develop some degree of autoimmune postpartum thyroiditis (23) .
Today, mild thyroid failure is thought to be a relatively common condition and an increasing number of studies are actively investigating its epidemiology, potential effects, and treatment options. Those clinicians who lean toward initiating thyroxine therapy will point out the potential for inexorable progression of mild thyroid failure into overt hypothyroidism with its attendant symptoms, pathophysiological consequences, and sequelae. However, not all TSH elevations may be permanent or progressive. Those patients who have positive TPO antibodies are at particular risk for progression, often within a few years (24) . Patients with systemic illness of a wide variety of causes will have initial TSH suppression as part of the "sick euthyroid syndrome" and subsequently will have modest elevations in TSH during recovery (25, 26) . Thus, a blood TSH level measured during the recovery period may give a false impression of thyroid failure. Consequently, the management of a single mildly elevated TSH should not be immediate initiation of treatment with thyroxine, but rather confirmation of the elevated TSH at a follow-up visit 30 to 60 days later. In view of the effects of illness on thyroid function tests (25) , a diagnosis of subclinical hypothyroidism should not be made in hospitalized patients, but should be reserved for the outpatient setting.
The previously mentioned expert consensus panel (18) concluded that there was good evidence that patients with slight elevations of TSH Ͼ4.5 will progress to overt hypothyroidism and that levothyroxine therapy would prevent symptoms but felt that there was little convincing evidence that early treatment provided benefit. Those endocrinologists disagreeing with this conclusion hold that there have been extensive clinical studies and reviews indicating both the abnormalities present in mild thyroid failure and the benefits of thyroxine treatment (12) (13) (14) (15) (27) (28) (29) (30) (31) (32) (33) (34) (35) as well as more recent studies supporting their position since the consensus panel was convened (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) . They argue further that the panel recommendations are inconsistent in accepting the practice of achieving a goal or target TSH range of 1.0 to 1.5 mU/L in patients already on thyroxine therapy, whereas they refuse to accept TSH levels of 3 to 10 mU/L as abnormal in patients not on thyroxine therapy. One thing that all parties to this controversy can agree on is the need for future large-scale, carefully constructed and performed studies (18) (19) (20) (21) . Until those data become available, consideration of a more precisely determined reference range for TSH of 0.3 to 2.5 will permit detection of individuals at risk of overt thyroid disease and should prompt their further follow up to confirm progression into thyroid dysfunction and then justify initiation of therapy. We will likely never have an absolute cutoff value for TSH distinguishing "normal" from "abnormal." However, recognition that the mean of normal TSH values is 1.18 mU/L in blacks and 1.40 mU/L in whites (9) and that greater than 95% of the normal population will have a TSH level less than 2.5 mU/L (10) clearly implies that anyone with a higher value should be assessed for early thyroid failure. We believe that a TSH level between 5 and 10 deserves confirmation and, if confirmed, warrants treatment.
Some of the clinical and laboratory abnormalities with potential long-term consequences that have been associated with even mild hypothyroidism include an abnormal lipid profile that can be seem to improve with T4 treatment (13, 34, 40) . Such abnormalities in both total and low-density lipoprotein cholesterol and in apolipoproteins presumably could translate into an increased risk for coronary artery disease. One study (35) described an increased inciThyroid Disease in Women Y CME Review Articledence of aortic atherosclerosis (odds ratio [OR]: 1.7) and myocardial infarction (OR: 2.3) for women who met the criteria for mild thyroid failure. There was an even higher odds ratio for risk in those patients with elevated antithyroid antibodies. Myocardial performance may also be adversely influenced by mild hypothyroidism, and improvement in both systolic and diastolic function has been documented after treatment with levothyroxine (28, 29) . Other studies claim improvement with therapy in symptoms of depression and in impaired cognitive functions such as memory (46) , improved muscle energy utilization with reduced fatigue, and beneficial effects on infertility and pregnancy outcomes (47) have been described.
In appropriate dosage, there should be no concerns about the effects of levothyroxine replacement therapy on either the cardiovascular system or on bone mineral density. The evidence available to date indicates that even suppressive doses of levothyroxine have not been associated with loss of bone density in premenopausal women (48) . Postmenopausal women are at risk of loss of bone on high or TSH-suppressive dosage of levothyroxine, but that risk is significantly attenuated by concomitant estrogen replacement or therapy with raloxifene or bisphosphonates. There is little risk of bone loss with replacement dosage (TSH of 0.5-1.5 mU/L) even in postmenopausal women (49) .
One controversial question relates to the indications for finding patients with mild thyroid failure by screening the general population and whether such screening is cost-effective (50-52). The American Thyroid Association recommends screening by a measurement of TSH every 5 years for all adults (especially women) over the age of 35 (53) . The American Association of Clinical Endocrinologists (54) and the American Academy of Family Practice (55) recommend screening older patients, and the American College of Physicians recommends case finding in women over 50 years of age (56) . The American College of Obstetrics & Gynecology (ACOG) has not yet come out in favor of routine screening of pregnant women or women who plan to become pregnant. The ACOG guidance is consistent with case finding in patients with a history of thyroid disease or symptoms of thyroid disease (57) . The latter indication would tend to provide broad license to screen because virtually all patients report fatigue, and fatigue is a symptom of thyroid disease. Personally, we agree with others (58) who recommend TSH screening in pregnant women and then measuring anti-TPO antibodies should the TSH level be Ͼ3.0 mU/L. This appears prudent in view of the high frequency of Hashimoto thyroiditis in the United States and in view of studies (47, 59, 60) implicating mild thyroid deficiency in pregnant women with impaired neuropsychologic development of their newborn, and the more recent study by Casey et al (61) describing an association between subclinical hypothyroidism and preterm delivery. Given the potential impact of even mild thyroid failure on outcome of pregnancy, we hope that the ACOG might reconsider its position, although there continues to be resistance to do so (62) .
Danese et al (63) have proposed that screening with TSH is as cost-effective as screening for breast cancer or hypertension. Until this argument might be definitively settled, we believe that "screening" should be confined to individuals who may be at higher risk for mild thyroid failure. In addition to pregnant women, this would include the elderly, women over age 35, those with a family or personal history of thyroid disease, patients with diabetes mellitus, cardiovascular dysfunction, hypercholesterolemia, and in other disorders that occur with increased frequency in patients with Hashimoto disease such as diabetes mellitus, Sjögren syndrome, Addison disease, or pernicious anemia. Most importantly, screening of pregnant women with any history of autoimmune thyroid disease before pregnancy is clearly warranted (64) .
